Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer

• Published in: Cancer research communications 2022-09, Vol.2 (9), p.979-986
• Main Authors: Morris, Van K, Overman, Michael J, Lam, Michael, Parseghian, Christine M, Johnson, Benny, Dasari, Arvind, Raghav, Kanwal, Kee, Bryan K, Huey, Ryan, Wolff, Robert A, Shen, John Paul, Li, June, Zorrilla, Isabel, Tzeng, Ching-Wei D, Tran Cao, Hop S, Chun, Yun Shin, Newhook, Timothy E, Vauthey, Nicolas, Duose, Dzifa, Luthra, Raja, Haymaker, Cara, Kopetz, Scott
• Format: Article
• Language: English
• Subjects: Colonic Neoplasms; Colorectal Neoplasms - drug therapy; Humans; Immunologic Factors - therapeutic use; Liver Neoplasms - drug therapy; Rectal Neoplasms; Tumor Microenvironment
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.crc-22-0194

Identification of circulating tumor DNA (ctDNA) following curative intent therapies is a surrogate for microscopic residual disease for patients with metastatic colorectal cancer (mCRC). Preclinically, in micrometastatic microsatellite stable (MSS) CRC, increased TGF-β signaling results in exclusion of anti-tumor cytotoxic T cells from the tumor microenvironment. Bintrafusp alfa (BA) is a bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor ("TGF-β trap") and anti-PD-L1 antibody. Patients with liver-limited, MSS mCRC and with detected ctDNA after complete resection of all known tumors and standard-of-care therapy were treated with 1200 mg of BA intravenously every 14 days for six doses. The primary endpoint was ctDNA clearance. Radiographic characteristics at recurrence were compared using independent t-tests to historical data from a similar cohort of patients with liver-limited mCRC who underwent observation. Only 4 of 15 planned patients received BA before the study was stopped early for loss of equipoise. There was no grade ≥3 AE. None of the patients cleared ctDNA. All patients developed radiographic recurrence by the first planned restaging. Although not detectable at prior to treatment, TGFβ3 was found in circulation in all patients at cycle 2 day 1. Compared to a historical cohort, patients administered BA developed more metastases (15 versus 2, p=0.005) and greater tumor volumes (9 cm vs 2 cm, p=0.05). Treatment with BA in patients with ctDNA-detected, liver-limited mCRC did not clear ctDNA and was associated with large-volume recurrence, highlighting the potential context-specific complexity of dual TGF-β and PD-L1 inhibition.